Core Insights - Elevation Oncology is developing EO-1022, a differentiated HER3 antibody-drug conjugate (ADC) aimed at treating solid tumors, including breast cancer and non-small cell lung cancer, with an Investigational New Drug (IND) application expected to be filed in 2026 [1][5][6] Company Overview - Elevation Oncology focuses on discovering and developing selective cancer therapies for patients with significant unmet medical needs [6] - The company is leveraging advanced site-specific conjugation technology licensed from Synaffix B.V. to enhance the efficacy of EO-1022 [2][5] Product Details - EO-1022 consists of seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody, conjugated to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4 [2][5] - The ADC is designed to target HER3-expressing solid tumors, providing a potential new treatment option for patients who are refractory to existing HER3-targeting agents [3][5] Upcoming Presentation - Preclinical data for EO-1022 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25-30 in Chicago, Illinois [1][4] - The late-breaking abstract will be available on the AACR website starting April 25, 2025 [4][8]
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025